Transfusion medicine

Global Blood Transfusion Devices Market Analysis 2020-2025 - The Pathogen Reduction System is Expected to Witness Healthy Growth - ResearchAndMarkets.com

Friday, May 29, 2020 - 11:58am

The "Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The rise in the number of blood disorders, such as anemia, leukopenia, erythrocytosis, leukocytosis, and thrombocytosis is also boosting the blood transfusion market.
  • The pathogen reduction system segment of the blood transfusion market is believed to witness a healthy growrh over the forecast period.
  • Companies like Immucor Inc., Becton Dickinson, B. Braun, Terumo Corporation, and Grifols SA., hold a significant share in the blood transfusion market.

Haemonetics Announces Sale Of U.S. Blood Donor Management Software Solution Assets To The GPI Group

Thursday, May 28, 2020 - 9:18pm

BOSTON, May 28, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell certain blood donor management software solution assets within its Blood Center business unit to the GPI Group (GPI: IM).

Key Points: 
  • BOSTON, May 28, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell certain blood donor management software solution assets within its Blood Center business unit to the GPI Group (GPI: IM).
  • GPI is aleadingcompanyin providing IT Solutions supporting Healthcare and Social Services,listed on the MTAmarket of Borsa Italiana.
  • These products are sold predominantly in the U.S. and provide a range of solutions to optimize blood donor collection centers' blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution.
  • Hemasoft is a U.S. company providing specialized web-based software solutions for blood donor centers, blood banks, transfusion services, cell therapy labs and tissue banks.

Octapharma USA & BioMatrix Support Research Focused on COVID-19 & Myocardial Dysfunction

Thursday, May 28, 2020 - 2:03pm

Octapharma USA and BioMatrix Specialty Pharmacy are supporting a new investigator-initiated research study led by Kelly McCants, M.D., Medical Director of the Norton Heart & Vascular Institute in Louisville, Ky., focused on treating patients with the coronavirus (COVID-19) and presenting with COVID-19-associated myocardial dysfunction.

Key Points: 
  • Octapharma USA and BioMatrix Specialty Pharmacy are supporting a new investigator-initiated research study led by Kelly McCants, M.D., Medical Director of the Norton Heart & Vascular Institute in Louisville, Ky., focused on treating patients with the coronavirus (COVID-19) and presenting with COVID-19-associated myocardial dysfunction.
  • Octapharma USA is donating Octagam 10% and cutaquig 16.5%, the companys intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), for the study.
  • We are extremely excited to partner with BioMatrix and Octapharma in this ground-breaking endeavor, said Dr. McCants.
  • BioMatrix welcomes the opportunity to participate in research on mitigating myocardial damage from COVID-19, said Marc Stranz, PharmD, Chief Clinical Officer at BioMatrix.

Bio Products Laboratory Announces Launch of ALBUMINEX® 5% and ALBUMINEX® 25% With Supply Immediately Available in the United States

Wednesday, May 27, 2020 - 7:29pm

Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.

Key Points: 
  • Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.
  • No cases of transmission of viral diseases or CJD have ever been identified for ALBUMINEX 5% or ALBUMINEX 25%.
  • BPL USA is part of a global company, Bio Products Laboratory, which boasts a vibrant 60-year heritage in plasma research, technology, and manufacturing.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/bio-products-laboratory-announce...
    SOURCE Bio Products Laboratory USA Inc.

Immune Thrombocytopenia Market is Anticipated to Grow by 2030 Owing to a Rich and Robust Pipeline

Wednesday, May 27, 2020 - 3:00pm

LAS VEGAS, May 27, 2020 /PRNewswire/ -- DelveInsight has added a new report Immune Thrombocytopenia (ITP) Market Insights , Epidemiology and Market Forecast2030 in its vast repository of market research reports.

Key Points: 
  • LAS VEGAS, May 27, 2020 /PRNewswire/ -- DelveInsight has added a new report Immune Thrombocytopenia (ITP) Market Insights , Epidemiology and Market Forecast2030 in its vast repository of market research reports.
  • The total Immune Thrombocytopenia prevalent population in the 7MM is expected to reach up to184,676in 2020.
  • The Immune Thrombocytopenia market size in the 7MM wasbe USD 2,527.72 million in 2017.
  • Present Immune Thrombocytopenia Market has several approved therapies that help increasing the count of platelets.

Immune Thrombocytopenia Market is Anticipated to Grow by 2030 Owing to a Rich and Robust Pipeline

Wednesday, May 27, 2020 - 3:00pm

The total Immune Thrombocytopenia prevalent population in the 7MM is expected to reach up to184,676in 2020.

Key Points: 
  • The total Immune Thrombocytopenia prevalent population in the 7MM is expected to reach up to184,676in 2020.
  • The Immune Thrombocytopenia market size in the 7MM wasbe USD 2,527.72 million in 2017.
  • The United States is expected to account for the maximum prevalent Immune Thrombocytopenia cases among 7MM countries by 2020.
  • Present Immune Thrombocytopenia Market has several approved therapies that help increasing the count of platelets.

Therapeutic Plasma Exchange Market Assessment 2015-2025: Includes Company Profilings of 15 Prominent Players

Tuesday, May 26, 2020 - 11:00pm

The global market for therapeutic plasma exchange is anticipated to grow at brisk rate during the forecast period.

Key Points: 
  • The global market for therapeutic plasma exchange is anticipated to grow at brisk rate during the forecast period.
  • Therapeutic plasma exchange or Plasmapheresis, the process of replacing blood in the body, has witnessed significant rise in the demand on account of increasing chronic diseases, for instance, Guillain Barre Syndrome (GBS); thereby, positively influencing the therapeutic plasma exchange market across the globe.
  • The Global Therapeutic Plasma Exchange Market is segmented on the basis of technique, indication, gender, end-use and region.
  • To maintain their position in the Global Therapeutic Plasma Exchange Market, the leading players are adopting several organic and inorganic strategies such as mergers, acquisitions, etc.

Headspring and PPTA partner to bring a new global plasma donation system to market

Tuesday, May 26, 2020 - 4:23pm

This new system will have a tangible impact on the plasma collection process and the patients who depend on PPTs.

Key Points: 
  • This new system will have a tangible impact on the plasma collection process and the patients who depend on PPTs.
  • Headspring will replace the legacy system and develop and maintain a single, fully responsive web application system that gives plasma collectors seamless access to two databases: the National Donor Deferral Registry (NDDR) and the Cross Donation Check System (CDCS).
  • "PPTA is looking forward to working with Headspring to develop this advanced system," remarked Joshua Penrod, PPTA Senior Vice President, Source and International Affairs.
  • PPTA also administers standards and programs that help ensure the quality and safety of plasma protein therapies, donors, and patients.

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

Tuesday, May 26, 2020 - 2:00pm

Coalition members developing an H-Ig include CoVIg-19 Plasma Alliance (CSL Behring, Takeda, ADMA Biologics, Biopharma Plasma, Biotest, BPL, GC Pharma, Octapharma and Sanquin) and Grifols.

Key Points: 
  • Coalition members developing an H-Ig include CoVIg-19 Plasma Alliance (CSL Behring, Takeda, ADMA Biologics, Biopharma Plasma, Biotest, BPL, GC Pharma, Octapharma and Sanquin) and Grifols.
  • Uber Health has contributed 25,000 free, roundtrip Uber rides to and from plasma donor centers for those potentially eligible to donate.
  • "AABB is proud to support blood centers throughout the country that are collecting potentially lifesaving plasma from COVID-19 survivors.
  • We are committed to supporting the survivors who will be participating in this critical campaign to donate their plasma."

Global Therapeutic Plasma Exchange Market by Technique, Indication, Gender, End-use and Region - Forecast to 2025 - ResearchAndMarkets.com

Monday, May 25, 2020 - 2:39pm

The global market for therapeutic plasma exchange is anticipated to grow at brisk rate during the forecast period.

Key Points: 
  • The global market for therapeutic plasma exchange is anticipated to grow at brisk rate during the forecast period.
  • Therapeutic plasma exchange or Plasmapheresis, the process of replacing blood in the body, has witnessed significant rise in the demand on account of increasing chronic diseases, for instance, Guillain Barre Syndrome (GBS); thereby, positively influencing the therapeutic plasma exchange market across the globe.
  • The Global Therapeutic Plasma Exchange Market is segmented on the basis of technique, indication, gender, end-use and region.
  • To maintain their position in the Global Therapeutic Plasma Exchange Market, the leading players are adopting several organic and inorganic strategies such as mergers, acquisitions, etc.